When a new drug promotes the integration of treatment modalities: Suboxone and harm reduction

Heroin Addiction and Related Clinical Problems

Volumn 10, Issue 3, 2008, Pages 5-11

  Maremmani, Icro ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Full and partial opioid agonists; Harm reduction; Heroin addiction; Opioid antagonists; Opioid receptors; Pharmacology; Suboxone

Indexed keywords

ALCOHOL; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; METHADONE; NALOXONE; NALTREXONE; PARTIAL AGONIST;

ABSTINENCE; ALCOHOL ABUSE; DRUG ABUSE; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG DEPENDENCE TREATMENT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INFORMATION; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; DRUG SELF ADMINISTRATION; EUPHORIA; GENERAL PRACTITIONER; HARM REDUCTION; HEROIN DEPENDENCE; HUMAN; INTRAVENOUS DRUG ABUSE; MORTALITY; PATIENT ABUSE; PATIENT COUNSELING; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SUBSTANCE ABUSE; TREATMENT CONTRAINDICATION; WITHDRAWAL SYNDROME;

EID: 56049124615     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. AURIACOMBE M., FATSEAS M., DUBERNET J., DAULOUEDE J. P., TIGNOL J. (2004): French field experience with buprenorphine. Am J Addict. 13 S17-S28.
2. BELL J., BYRON G., GIBSON A., MORRIS A. (2004): A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev. 23:(3) 311-317.
3. BICKEL W. K., STITZER M. L., BIGELOW G. E., LIEBSON I. A., JASINSKI D. R., JOHNSON R. E. (1988): Buprenorphine: dose-related blockade of opioid challenge in opioid dependent humans. J Psychopharmaco Exper Ther (247) 47-53.
4. BOZARTH M. A., WISE R. (1981): Heroin reward is dependent on a dopaminergic substrate. Life Sci. 29 1881-1886.
5. BROWN P. H., BROESKE P. H. (1996): Howard Hughes: The Untold Story. Penguin Books USA Inc., New York, NY.
6. BROWN S. L., VAN PRAAG H. M. (1991): The role of serotonin in psychiatric disorders. Brunner-Mazel Publ., New York.
7. DEMARIA P. A., PATKAR A. A. (2008): The implementation of buprenorphine/naloxone in college health practice. J Am Coll Health. 56:(4) 391-393.
8. DOLE V. P. (1980): Addictive behaviour. Sci Am. 243 138-154.
9. DOLE V. P., NYSWANDER M. E. (1967): Heroin Addiction: A Metabolic Disease. Arch Intern Med. 120 19-24.
10. DOLE V. P., NYSWANDER M. E., KREEK M. J. (1966): Narcotic Blockade. Arch Intern Med. 118 304-309.
11. DOLE V. P., NYSWANDER M. E., WARNER A. (1968): Successful treatment of 750 criminal addicts. JAMA. 206 2708-2711.
12. FONTAA V., BRONNER C. (2001): Persistance de la pratique d'injection chez des patients substitués par méthadone ou buprénorphine haut dosage. Ann Med Interne. 152:(7S) 2S59-52S69.
13. GARDNER T., KOSTEN T. (2007): Buprenorphine for Dual Dependency: Cocaine, Alcohol and Opiates. Heroin Addict Relat Clin Probl. 9:(2) 11-16.
14. GASTFRIEND D. R., MENDELSON J. H., MELLO N. K., AL. E. (1993): Buprenorphine pharmacotherapy for concurrent heroin and cocaine dependence. Am J Addict. 2 269-278.
15. GOLDMAN F. R., THISTEL C. I. (1978): Diversion of methadone: illicit methadone use among applicants to two metropolitan drug abuse programs. Int J Addict. 13:(6) 855-862.
16. GREENSTEIN R. A., RESNICK R. B., RESNICK E. (1984): Methadone and Naltrexone in the treatment of heroine dependence. Psychiatr Clin North Am 671-679.
17. INCIARDI J. A. (1977): The development of Methadone Treatment. In: NIDA (Ed.) Methadone diversion: experiences and issues. DHEW Publication, Rockville,Md. pp. 9-11.
18. JENKINSON R. A., CLARK N. C., FRY C. L., DOBBIN M. (2005): Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction. 100:(2) 197-205.
19. KOSTEN T. R., ROSEN M. I., SCHOTTENFELD R. S., ZIEDONIS D. (1992): Buprenorphine for cocaine and opiate dependence. Psychopharmacol Bull. 28 15-19.
20. LEAVITT S. B., SHINDERMAN M., MAXWELL S., EAP C. B., PARIS P. (2000): When "enough" is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med. 67:(5-6) 404-411.
21. MAREMMANI I., BALESTRI C., SBRANA A., TAGLIAMONTE A. (2003): Substance (ab)use during methadone and naltrexone treatment. Interest of adequate methadone dosage. Journal of Maintenance in the Addictions. 2:(1-2) 19-36.
22. MAREMMANI I., BARRA M., BIGNAMINI E., CONSOLI A., DELL'AERA S., DERUVO G., FANTINI F., FASOLI M. G., GATTI R., GESSA G. L., GUELFI G. P., JARRE P., MICHELAZZI A., MOLLICA R., NARDINI R., PANI P. P., POLIDORI E., SIRAGUSA C., SPAZZAPAN B., STARACE F., TAGLIAMONTE A., TIDONE L., VENDRAMIN A. (2002): Clinical foundations for the use of methadone. Italian Consensus Panel on Methadone Treatment. Heroin Addict Relat Clin Probl. 4:(2) 19-31.
23. MAREMMANI I., MARINI G., CASTROGIOVANNI P., DELTITO J. (1996): The effectiveness of the combination Fluoxetine-Naltrexone in Bulimia Nervosa. Eur Psychiatry. 11 322-324.
24. MAREMMANI I., MARINI G., FORNAI F. (1998): Naltrexone induced Panic Attacks. Am J Psychiatry. 155:(3) 447.
25. MAREMMANI I., PACINI M., GIUNTOLI G., LOVRECIC M., PERUGI G. (2004): Naltrexone as maintenance therapy for heroin addiction: Predictors of response. Heroin Addict Relat Clin Probl. 6:(1) 43-52.
26. MAREMMANI I., PACINI M., LUBRANO S., GIUNTOLI G., LOVRECIC M. (2002): Harm reduction and specific treatments for heroin addiction. Different approaches or levels of intervention? An illness-centred perspective. Heroin Addict Relat Clin Probl. 4:(3) 5-11.
27. MAREMMANI I., ZOLESI O., DAINI L., CASTROGIOVANNI P., TAGLIAMONTE A. (1995): Fluoxetine improves outcome in Addicted Patients Treated With Opioid Antagonists. Am J Addict. 4:(3) 267-271.
28. MARTIN W. R. (1979): History and development of mixed opioid agonists, partial agonists and antagonists. Br J Clin Pharmacol. 7 Suppl 3 273S-279S.
29. MENDELSON J., UPTON R. A., EVERHART E. T., JACOB P., 3RD, JONES R. T. (1997): Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 37:(1) 31-37.
30. MIOTTO K., MCCANN M. J., RAWSON R. A., FROSCH D., LING W. (1997): Overdose, suicide attemps and death among a cohort of naltrexone treated opioid addicts. Drug Alcohol Depend. 45:(1-2) 131-134.
31. MUHLEISEN P., SPENCE J., NIELSEN S. (2003): Crushing buprenorphine tablets. Drug Alcohol Rev. 22:(4) 471-472.
32. NESPOR K., CSEMY L. (2005): Buprenorphine abuse has become a problem in Czech Republic. Psychiatrie. 9:(4) 333-334.
33. O'CONNOR J. J., MOLONEY E., TRAVERS R., CAMPBELL A. (1988): Buprenorphine abuse among opiate addicts. Br J Addict. 83:(9) 1085-1087.
34. O'HARE P. (1994): Starring Harm Reduction (Editorial). Int J Drug Policy. 5 199-200.
35. PARRINO M. W. (1993): State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series, 1. U.S. Department of Health and Human Services, Rockville, MD.
36. PELES E., BODNER G., ADELSON M. (2005): Correlation between high methadone dose and methadone blood level in methadone maintenance treatment patients. Heroin Addict Relat Clin Probl. 7:(3) 27-32.
37. RENO R. R., AIKEN L. S. (1993): Life activities and life quality of heroin addicts in and out of methadone treatment. Int J Addict. 28:(3) 211-232.
38. RITTER A., DI NATALE R. (2005): The relationship between take-away methadone policies and methadone diversion. Drug Alcohol Rev. 24:(4) 347-352.
39. ROBINSON G. M., DUKES P. D., ROBINSON B. J., COOKE R. R., MAHONEY G. N. (1993): The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend. 33:(1) 81-86.
40. ROSENBAUM M., WASHBURN A., KNIGHT K., KELLEY M., IRWIN J. (1996): Treatment as harm reduction, defunding as harm maximization: the case of methadone maintenance. J Psychoactive Drugs. 1996 Jul-Sep;28(3):241-9. J Psychoactive Drugs. 28:(3) 241-249.
41. SIDEROFF S. N., CHARAUWASTA V. C., FARVIK M. E. (1978): Craving in heroin addicts maintained on the opiate antagonist Naltrexone. Am J Drug Alcohol Abuse. 5 415-423.
42. STRANG J. (1985): Abuse of buprenorphine. Lancet. 2:(8457) 725.
43. TACKE U. (2002): Abuse of buprenorphine by intravenous injection - the French connection. Addiction. 97:(10) 1355.
44. TORRENS M., DOMINGO-SALVANY A., ALONSO J., CASTILLO C., SAN L. (1999): Methadone and quality of life. Lancet. 353:(9158) 1101.
45. WALSH S. L., PRESTON K. L., BIGELOW G. E., STITZER M. L. (1995): Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 274:(1) 361-372.
46. WALSH S. L., PRESTON K. L., STITZER M. L., CONE E. J., BIGELOW G. E. (1994): Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 55:(5) 569-580.
47. WARD J., MATTICK R. P., HALL W. (1994): The effectiveness of methadone maintenance treatment: an overview. Drug Alcohol Rev. 13:(3) 327-335.
48. WELLS B. (1994): Methadone Maintenance Treatment: harm reduction or rehabilitation? Addiction. 89 806.
49. WILCOX R. E., ERIKSON C. K. (2004): Prevention of relapse to addiction: information for the practitioner. Tex Med. 100:(2) 52-61.
50. WOLFF K., SANDERSON M., HAY A. W. M., RALSTRICK D. (1991): Methadone concentration in plasma and their relationship to drug dosage. Clinical Chemistry. 37:((2)) 205-209.
51. ZUBIETA J., GREENWALD M. K., LOMBARDI U., WOODS J. H., KILBOURN M. R., JEWETT D. M., KOEPPE R. A., SCHUSTER C. R., JOHANSON C. E. (2000): Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology. 23:(3) 326-334.